This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan ( an angiotensin II receptor blocker ( ARB ) ) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease ( CKD ) over a @-year period .